Software - Application
Compare Stocks
5 / 10Stock Comparison
WEAV vs SCHW vs TMDX vs WELL vs PHR
Revenue, margins, valuation, and 5-year total return — side by side.
Financial - Capital Markets
Medical - Devices
REIT - Healthcare Facilities
Medical - Healthcare Information Services
WEAV vs SCHW vs TMDX vs WELL vs PHR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Software - Application | Financial - Capital Markets | Medical - Devices | REIT - Healthcare Facilities | Medical - Healthcare Information Services |
| Market Cap | $477M | $159.04B | $2.52B | $149.25B | $593M |
| Revenue (TTM) | $249M | $26.00B | $636M | $11.63B | $463M |
| Net Income (TTM) | $-25M | $8.85B | $172M | $1.43B | $-5M |
| Gross Margin | 72.3% | 75.4% | 59.1% | 39.1% | 68.2% |
| Operating Margin | -11.0% | 29.6% | 14.9% | 4.4% | -1.9% |
| Forward P/E | 36.2x | 14.9x | 29.9x | 78.4x | 30.6x |
| Total Debt | $87M | $45.13B | $470M | $21.38B | $18M |
| Cash & Equiv. | $55M | $42.08B | $488M | $5.03B | $84M |
WEAV vs SCHW vs TMDX vs WELL vs PHR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Nov 21 | May 26 | Return |
|---|---|---|---|
| Weave Communication… (WEAV) | 100 | 34.1 | -65.9% |
| The Charles Schwab … (SCHW) | 100 | 115.6 | +15.6% |
| TransMedics Group, … (TMDX) | 100 | 330.8 | +230.8% |
| Welltower Inc. (WELL) | 100 | 267.5 | +167.5% |
| Phreesia, Inc. (PHR) | 100 | 17.0 | -83.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: WEAV vs SCHW vs TMDX vs WELL vs PHR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
WEAV lags the leaders in this set but could rank higher in a more targeted comparison.
SCHW carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 255.2% 10Y total return vs TMDX's 226.0%
- Lower P/E (14.9x vs 30.6x)
- 1.4% yield, vs WELL's 1.3%, (3 stocks pay no dividend)
- 232.8% ROA vs WEAV's -12.1%, ROIC 6.0% vs -23.4%
TMDX is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 37.1%, EPS growth 382.2%, 3Y rev CAGR 86.4%
- 37.1% revenue growth vs SCHW's 1.9%
- 27.0% margin vs WEAV's -10.1%
WELL ranks third and is worth considering specifically for income & stability and sleep-well-at-night.
- Dividend streak 2 yrs, beta 0.13, yield 1.3%
- Lower volatility, beta 0.13, Low D/E 49.5%, current ratio 5.34x
- Beta 0.13, yield 1.3%, current ratio 5.34x
- Beta 0.13 vs WEAV's 1.71, lower leverage
Among these 5 stocks, PHR doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 37.1% revenue growth vs SCHW's 1.9% | |
| Value | Lower P/E (14.9x vs 30.6x) | |
| Quality / Margins | 27.0% margin vs WEAV's -10.1% | |
| Stability / Safety | Beta 0.13 vs WEAV's 1.71, lower leverage | |
| Dividends | 1.4% yield, vs WELL's 1.3%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +42.7% vs PHR's -59.7% | |
| Efficiency (ROA) | 232.8% ROA vs WEAV's -12.1%, ROIC 6.0% vs -23.4% |
WEAV vs SCHW vs TMDX vs WELL vs PHR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
WEAV vs SCHW vs TMDX vs WELL vs PHR — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
WELL leads in 2 of 6 categories
TMDX leads 1 • WEAV leads 0 • SCHW leads 0 • PHR leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — SCHW and TMDX each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SCHW is the larger business by revenue, generating $26.0B annually — 104.5x WEAV's $249M. TMDX is the more profitable business, keeping 27.0% of every revenue dollar as net income compared to WEAV's -10.1%. On growth, WELL holds the edge at +40.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $249M | $26.0B | $636M | $11.6B | $463M |
| EBITDAEarnings before interest/tax | -$15M | $12.8B | $115M | $2.8B | $20M |
| Net IncomeAfter-tax profit | -$25M | $8.9B | $172M | $1.4B | -$5M |
| Free Cash FlowCash after capex | $10M | $9.7B | $151M | $2.5B | $42M |
| Gross MarginGross profit ÷ Revenue | +72.3% | +75.4% | +59.1% | +39.1% | +68.2% |
| Operating MarginEBIT ÷ Revenue | -11.0% | +29.6% | +14.9% | +4.4% | -1.9% |
| Net MarginNet income ÷ Revenue | -10.1% | +22.9% | +27.0% | +12.3% | -1.2% |
| FCF MarginFCF ÷ Revenue | +3.9% | +7.9% | +23.8% | +21.9% | +9.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +17.4% | — | +21.2% | +40.3% | +12.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +41.7% | +41.5% | -71.4% | +22.5% | -88.3% |
Valuation Metrics
Evenly matched — SCHW and PHR each lead in 2 of 6 comparable metrics.
Valuation Metrics
At 15.0x trailing earnings, TMDX trades at a 90% valuation discount to WELL's 153.3x P/E. On an enterprise value basis, SCHW's 17.8x EV/EBITDA is more attractive than WELL's 66.4x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $477M | $159.0B | $2.5B | $149.2B | $593M |
| Enterprise ValueMkt cap + debt − cash | $509M | $162.1B | $2.5B | $165.6B | $526M |
| Trailing P/EPrice ÷ TTM EPS | -16.39x | 29.93x | 14.97x | 153.25x | -9.64x |
| Forward P/EPrice ÷ next-FY EPS est. | 36.21x | 14.86x | 29.86x | 78.42x | 30.57x |
| PEG RatioP/E ÷ EPS growth rate | — | 13.07x | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 17.76x | 18.42x | 66.40x | — |
| Price / SalesMarket cap ÷ Revenue | 2.00x | 6.12x | 4.16x | 13.99x | 1.41x |
| Price / BookPrice ÷ Book value/share | 5.62x | 3.39x | 6.25x | 3.35x | 2.14x |
| Price / FCFMarket cap ÷ FCF | 31.48x | 77.58x | 18.86x | 52.41x | 71.47x |
Profitability & Efficiency
TMDX leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
SCHW delivers a 2.9% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-31 for WEAV. PHR carries lower financial leverage with a 0.07x debt-to-equity ratio, signaling a more conservative balance sheet compared to WEAV's 1.05x. On the Piotroski fundamental quality scale (0–9), SCHW scores 7/9 vs WEAV's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -30.9% | +2.9% | +41.9% | +3.5% | -1.7% |
| ROA (TTM)Return on assets | -12.1% | +2.3% | +15.8% | +2.3% | -1.3% |
| ROICReturn on invested capital | -23.4% | +6.0% | +18.8% | +0.5% | -23.3% |
| ROCEReturn on capital employed | -24.5% | +9.5% | +12.6% | +0.6% | -21.7% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 7 | 7 | 7 | 6 |
| Debt / EquityFinancial leverage | 1.05x | 0.93x | 0.99x | 0.49x | 0.07x |
| Net DebtTotal debt minus cash | $32M | $3.1B | -$19M | $16.3B | -$66M |
| Cash & Equiv.Liquid assets | $55M | $42.1B | $488M | $5.0B | $84M |
| Total DebtShort + long-term debt | $87M | $45.1B | $470M | $21.4B | $18M |
| Interest CoverageEBIT ÷ Interest expense | -20.26x | 3.05x | 33.15x | 0.26x | -1.01x |
Total Returns (Dividends Reinvested)
WELL leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in WELL five years ago would be worth $30,234 today (with dividends reinvested), compared to $1,994 for PHR. Over the past 12 months, WELL leads with a +42.7% total return vs PHR's -59.7%. The 3-year compound annual growth rate (CAGR) favors WELL at 42.5% vs PHR's -30.8% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -15.4% | -11.6% | -40.6% | +14.3% | -39.7% |
| 1-Year ReturnPast 12 months | -40.1% | +7.9% | -23.9% | +42.7% | -59.7% |
| 3-Year ReturnCumulative with dividends | +11.3% | +94.5% | +2.8% | +189.5% | -66.9% |
| 5-Year ReturnCumulative with dividends | -67.7% | +31.4% | +200.7% | +202.3% | -80.1% |
| 10-Year ReturnCumulative with dividends | -67.7% | +255.2% | +226.0% | +223.1% | -60.8% |
| CAGR (3Y)Annualised 3-year return | +3.6% | +24.8% | +0.9% | +42.5% | -30.8% |
Risk & Volatility
WELL leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
WELL is the less volatile stock with a 0.13 beta — it tends to amplify market swings less than WEAV's 1.71 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. WELL currently trades 97.0% from its 52-week high vs PHR's 30.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.71x | 0.72x | 1.59x | 0.13x | 0.79x |
| 52-Week HighHighest price in past year | $11.32 | $107.50 | $156.00 | $219.59 | $32.76 |
| 52-Week LowLowest price in past year | $4.24 | $83.19 | $70.00 | $142.65 | $7.77 |
| % of 52W HighCurrent price vs 52-week peak | +53.6% | +83.3% | +46.7% | +97.0% | +30.0% |
| RSI (14)Momentum oscillator 0–100 | 65.8 | 47.8 | 21.8 | 60.2 | 48.3 |
| Avg Volume (50D)Average daily shares traded | 1.6M | 9.3M | 1.1M | 2.6M | 1.9M |
Analyst Outlook
Evenly matched — SCHW and WELL each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: WEAV as "Buy", SCHW as "Buy", TMDX as "Buy", WELL as "Buy", PHR as "Buy". Consensus price targets imply 173.2% upside for PHR (target: $27) vs 6.3% for WELL (target: $227). For income investors, SCHW offers the higher dividend yield at 1.39% vs WELL's 1.30%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $9.00 | $119.11 | $144.75 | $226.50 | $26.86 |
| # AnalystsCovering analysts | 9 | 50 | 12 | 34 | 25 |
| Dividend YieldAnnual dividend ÷ price | — | +1.4% | — | +1.3% | — |
| Dividend StreakConsecutive years of raises | — | 0 | — | 2 | 1 |
| Dividend / ShareAnnual DPS | — | $1.24 | — | $2.76 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.0% | 0.0% | 0.0% |
WELL leads in 2 of 6 categories (Total Returns, Risk & Volatility). TMDX leads in 1 (Profitability & Efficiency). 3 tied.
WEAV vs SCHW vs TMDX vs WELL vs PHR: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is WEAV or SCHW or TMDX or WELL or PHR a better buy right now?
For growth investors, TransMedics Group, Inc.
(TMDX) is the stronger pick with 37. 1% revenue growth year-over-year, versus 1. 9% for The Charles Schwab Corporation (SCHW). TransMedics Group, Inc. (TMDX) offers the better valuation at 15. 0x trailing P/E (29. 9x forward), making it the more compelling value choice. Analysts rate Weave Communications, Inc. (WEAV) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — WEAV or SCHW or TMDX or WELL or PHR?
On trailing P/E, TransMedics Group, Inc.
(TMDX) is the cheapest at 15. 0x versus Welltower Inc. at 153. 3x. On forward P/E, The Charles Schwab Corporation is actually cheaper at 14. 9x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — WEAV or SCHW or TMDX or WELL or PHR?
Over the past 5 years, Welltower Inc.
(WELL) delivered a total return of +202. 3%, compared to -80. 1% for Phreesia, Inc. (PHR). Over 10 years, the gap is even starker: SCHW returned +255. 2% versus WEAV's -67. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — WEAV or SCHW or TMDX or WELL or PHR?
By beta (market sensitivity over 5 years), Welltower Inc.
(WELL) is the lower-risk stock at 0. 13β versus Weave Communications, Inc. 's 1. 71β — meaning WEAV is approximately 1187% more volatile than WELL relative to the S&P 500. On balance sheet safety, Phreesia, Inc. (PHR) carries a lower debt/equity ratio of 7% versus 105% for Weave Communications, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — WEAV or SCHW or TMDX or WELL or PHR?
By revenue growth (latest reported year), TransMedics Group, Inc.
(TMDX) is pulling ahead at 37. 1% versus 1. 9% for The Charles Schwab Corporation (SCHW). On earnings-per-share growth, the picture is similar: TransMedics Group, Inc. grew EPS 382. 2% year-over-year, compared to -11. 5% for Welltower Inc.. Over a 3-year CAGR, TMDX leads at 86. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — WEAV or SCHW or TMDX or WELL or PHR?
TransMedics Group, Inc.
(TMDX) is the more profitable company, earning 31. 4% net margin versus -13. 9% for Phreesia, Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SCHW leads at 29. 6% versus -13. 8% for PHR. At the gross margin level — before operating expenses — SCHW leads at 75. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is WEAV or SCHW or TMDX or WELL or PHR more undervalued right now?
On forward earnings alone, The Charles Schwab Corporation (SCHW) trades at 14.
9x forward P/E versus 78. 4x for Welltower Inc. — 63. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PHR: 173. 2% to $26. 86.
08Which pays a better dividend — WEAV or SCHW or TMDX or WELL or PHR?
In this comparison, SCHW (1.
4% yield), WELL (1. 3% yield) pay a dividend. WEAV, TMDX, PHR do not pay a meaningful dividend and should not be held primarily for income.
09Is WEAV or SCHW or TMDX or WELL or PHR better for a retirement portfolio?
For long-horizon retirement investors, Welltower Inc.
(WELL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 13), 1. 3% yield, +223. 1% 10Y return). Weave Communications, Inc. (WEAV) carries a higher beta of 1. 71 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (WELL: +223. 1%, WEAV: -67. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between WEAV and SCHW and TMDX and WELL and PHR?
These companies operate in different sectors (WEAV (Technology) and SCHW (Financial Services) and TMDX (Healthcare) and WELL (Real Estate) and PHR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: WEAV is a small-cap high-growth stock; SCHW is a mid-cap quality compounder stock; TMDX is a small-cap high-growth stock; WELL is a mid-cap high-growth stock; PHR is a small-cap high-growth stock. SCHW, WELL pay a dividend while WEAV, TMDX, PHR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.